What is Vaxess Technologies?
Vaxess Technologies is a pioneering biotechnology firm dedicated to the development of proprietary transdermal patch and applicator systems. By integrating advanced chemistry, immunology, and biomedical engineering, the company is creating a platform capable of delivering a wide range of therapies and vaccines without the need for refrigeration or professional administration. This approach addresses critical gaps in global healthcare infrastructure, particularly in environments where cold-chain storage is unavailable or where patient access to clinical settings is limited. As a key player in the Tough Tech ecosystem, Vaxess is transforming how medical interventions are deployed, moving toward a future where self-administration is both safe and effective.
How much funding has Vaxess Technologies raised?
Vaxess Technologies has raised a total of $158.9M across 10 funding rounds:
Private Equity
$862K
Series A
$82M
Debt
$150K
Series B
$27M
Other Financing Round
$10M
Other Financing Round
$9M
Other Financing Round
$12M
Other Financing Round
$9M
Debt
$7.9M
Private Equity (2016): $862K, investors not publicly disclosed
Series A (2019): $82M supported by The Engine and Bioinnovation Capital
Debt (2020): $150K featuring PPP
Series B (2022): $27M backed by Mission BioCapital, The Engine, and Global Health Investment Corporation
Other Financing Round (2023): $10M with participation from Mission BioCapital and RA Capital Management
Other Financing Round (2023): $9M led by RA Capital Management, The Engine, and Ulu Ventures
Other Financing Round (2024): $12M supported by Mission BioCapital, RA Capital Management, and Engine Ventures
Other Financing Round (2025): $9M featuring RA Capital Management and Engine Ventures
Debt (2025): $7.9M, investors not publicly disclosed
Key Investors in Vaxess Technologies
RA Capital Management
A multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, utilizing their internal think tank, TechAtlas, to guide strategic decisions.
Mission BioCapital
A venture capital firm providing early-stage capital to life science entrepreneurs, emphasizing mentorship and the acceleration of scientific breakthroughs through shared lab spaces and deep industry expertise.
The Engine
A venture firm built by MIT that invests in Tough Tech, focusing on transformative technologies that address fundamental challenges in human health, climate change, and advanced infrastructure.
What's next for Vaxess Technologies?
With the successful acquisition of $7.9M, Vaxess Technologies is entering a critical phase of commercialization and clinical validation. The company's strategic roadmap focuses on transitioning its laboratory-proven innovations into scalable, real-world applications. Future efforts will likely prioritize the expansion of its manufacturing footprint and the advancement of its pipeline through regulatory milestones. By maintaining its focus on Tough Tech principles, Vaxess is poised to disrupt the traditional pharmaceutical delivery market, potentially setting a new standard for patient-centric care and global health resilience.
See full Vaxess Technologies company page
